secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2025-04-23T23:59:59+00:00
Accession:  0000950170-25-057398
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Candel Therapeutics announces oral presentation of positive Phase 3 CAN-2409 data in prostate cancer at ASCO 2025
--------------------------------------------------------------------------------

- Phase 3 CAN-2409 data in localized prostate cancer accepted for oral presentation at ASCO 2025 (May 30-June 3, Chicago).
- Presenter is Theodore DeWeese, M.D., Dean and CEO of Johns Hopkins Medicine.
- Full abstracts released by ASCO on May 22, 2025 at 5:00 PM ET.
- Candel will post presentation details on its website after the event.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000095017025057398/0000950170-25-057398-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000095017025057398/cadl-20250423.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-057398

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer